Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Mesothelioma 1Endometrial Neoplasms 1Carcinosarcoma 1

Interventions

Specimen Handling 6Paclitaxel 6Magnetic Resonance Spectroscopy 5Nivolumab 4Carboplatin 4Biopsy 4pembrolizumab 2olaparib 2ceralasertib 2Taxes 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pamiparib 1durvalumab 1cobimetinib 1cediranib 1cabozantinib 1belinostat 1atezolizumab 1X-Rays 1Tissue Banks 1TIC10 compound 1Ipilimumab 1Immunoglobulin G 1Ifosfamide 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × DCC-2036 × Gynecologic × Clear all
NCT03601897 2024-12-27

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
177 enrolled 25 charts
BreastGynecologicSarcoma

Breast Neoplasms, Carcinosarcoma, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡